Routine use of urodynamic testing for overactive bladder (OAB) did not improve patient-reported outcomes when combined with comprehensive clinical assessment (CCA), a large randomized trial showed.

Bright Uro Inc. this month received Food and Drug Administration approval for its first product, the Glean Urodynamics System. It’s the biggest milestone to date for the Irvine medical device maker ...

Stony Brook performs first East Coast use of Glean Urodynamics. Wireless, catheter-free system monitors bladder in real time. Technology is designed to improve patient comfort and diagnostic precision ...

IRVINE, Calif.--(BUSINESS WIRE)--Bright Uro, a medical device company with a mission to transform care for lower urinary tract dysfunction (LUTD) through innovations in urodynamics, today announced ...